A Message From the Chair

Andre H. Goy, MD

The New Year often marks a new beginning. As we embrace 2018 I can’t help but feel grateful for all that 2017 has brought us in advancing the fight against hematologic malignancies and how we approach the treatment of blood cancers.

In the time since we last gathered for the International Congress on Hematologic Malignancies® we’ve seen more than 20 new approvals or indications in hematology. The strives we’ve made in 2017 and the hopes for 2018 make me proud to be a hematologist.

By the numbers, we start 2018 with 9 new approvals in leukemia, 7 new approvals in lymphoma, 2 CAR T cell therapies, as well as approvals for myeloproliferative neoplasms, myeloma, and graft versus host disease—just to name a few.

What makes 2018 even more exciting is the position of the International Congress on Hematologic Malignancies® to provide a timely update to all that you may have missed in the last calendar year.

Experts from around the world will gather to distill a year’s worth of progress into an unrivaled educational program. Join us in the Florida sun to learn the latest data, how to apply it to practice, and what to expect in the year to come.

In a year this groundbreaking, staying current is harder than ever. With the help of PER, we’ve made it easy. Happy 2018!

Sincerely, Andre H. Goy, MD